Exploring heart health in postmenopausal women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the role of purinergic signaling in diastolic heart failure among postmenopausal women. It focuses on how estrogen deficiency affects cardiac remodeling and mitochondrial metabolism, potentially leading to heart failure with preserved ejection fraction (HFpEF). Researchers will analyze cardiac tissue from patients undergoing cardiac surgery to understand the molecular pathways involved. The study aims to clarify the relationship between estrogen, purinergic signaling, and cardiovascular health in aging women.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients undergoing cardiac surgery under cardiopulmonary bypass.

Exclusion Criteria:

* Refusal to participate
* Emergency surgery
* Pre-existing heart block
* Preexisting atrial fibrillation
* Redo surgery
* Estrogen or hormone replacement therapy
* History of chronic heart failure
* History of major kidney disease

Where it's running

• Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Robina Matyal, MD — Beth Israel Deaconess Medical Center, Professor of Anesthesia
• Study coordinator: Robina Matyal, MD
• Email: rmatyal1@bidmc.harvard.edu
• Phone: 6176401208

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating Cardiac Contractility Modulation in Heart Failure Patients

  This study is testing a new heart treatment called Cardiac Contractility Modulation to see if it can help people with heart failure feel better and improve their heart function.

  Recruiting at 65 sites Impulse Dynamics · Birmingham, Alabama and 66 other locations · NCT05064709

• Remote rehabilitation for HFpEF patients using telerehabilitation

  A home-based telerehabilitation program is being tested to see if it is safe and helpful for people with heart failure with preserved ejection fraction.

  Recruiting at 3 sites American Heart of Poland · Chrzanów and 2 other locations · NCT07918209

• EDG-15400 in adults with HFpEF: a phase 2 study

  This phase 2 study tests different doses of EDG-15400 against placebo in adults with HFpEF to see if it is safe and tolerable.

  Recruiting at 4 sites Phase 2 Edgewise Therapeutics, Inc. · Birmingham, Alabama and 27 other locations · NCT07795814

• Incretin therapy with tirzepatide for obesity-related HFpEF

  A 15-month study will test whether tirzepatide helps people with obesity and HFpEF by reducing plasma volume.

  Recruiting Phase 4 Columbia University · New York, New York · NCT07554638

• Boosted exercise with group coaching for HFpEF

  This trial tests a blended, guided exercise program with group coaching and remote monitoring to see if it helps older adults with HFpEF improve activity and health at a lower cost.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT07413198

• Exercise cardiac MRI for heart failure with preserved ejection fraction

  This study will try low-field exercise cardiac MRI to see if it can diagnose, describe, and predict risk in people with HFpEF compared with those who have non-cardiac breathlessness and healthy volunteers.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07401771

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.